Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Bachem Holding
BANB
Bachem Holding
Strict Global Regulation And Rising Costs Will Impede Peptide Capacity
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
27 Jun 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CHF 58.00
17.4% overvalued
intrinsic discount
09 Aug
CHF 68.10
Loading
1Y
-13.9%
7D
1.4%
Author's Valuation
CHF 58.0
17.4% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CHF 58.0
17.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
1b
2014
2017
2020
2023
2025
2026
2028
Revenue CHF 1.1b
Earnings CHF 212.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
17.51%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.37%
Calculation
CHF 212.50m
Earnings '28
x
22.65x
PE Ratio '28
=
CHF 4.81b
Market Cap '28
CHF 4.81b
Market Cap '28
/
73.15m
No. shares '28
=
CHF 65.80
Share Price '28
CHF 65.80
Share Price '28
Discounted to 2025 @ 4.37% p.a.
=
CHF 57.88
Fair Value '25
